Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Health Catalyst Launches COVID-19 Patient Data Repository to Speed Vaccine Development

With a lack of historical population-based information to steer COVID-19 research, pharmaceutical companies are struggling to understand the everchanging virus as they work tirelessly to develop a vaccine in less than one year. Research teams can access near real-time COVID-19 patient data with Touchstone® for COVID-19 National Data Sets and Registry from over 80 million patients across the United States and three national data sources: John Hopkins University, The New York Times, and The COVID Tracking Project.

The Registry offers up-to-date, comprehensive data with outcome analysis and clinical trial analysis so research teams can stay up to date through every stage of the vaccine development process.

  • Be the first to comment

  • Be the first to like this

Health Catalyst Launches COVID-19 Patient Data Repository to Speed Vaccine Development

  1. 1. Health Catalyst Launches COVID-19 Patient Data Repository to Speed Vaccine Development
  2. 2. © 2020 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. Speeding COVID-19 Vaccine Development The World Economic Forum suggests the standard vaccination development process is 10 years. But, given the immense impact and transmissibility of COVID-19, pharma- ceutical companies are working to accelerate the process and release a vaccine in less than one year.
  3. 3. © 2020 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. Speeding COVID-19 Vaccine Development While the Food and Drug Administration (FDA) has rigorous safety and efficacy standards that pharmaceutical companies must meet before releasing a vaccine for public use, COVID-19 has forced a change in the rules in order to expedite the process.
  4. 4. © 2020 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. Speeding COVID-19 Vaccine Development With a shorter-than-normal time frame, research teams are under pressure to understand the novel coronavirus outbreak and develop a vaccine with little existing data or research. Pharmaceutical companies and health systems alike need the latest population- based research to keep up with the ever- changing nature of the virus as they develop a vaccine and care for patients.
  5. 5. © 2020 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. Speeding COVID-19 Vaccine Development In the past, pharmaceutical companies have relied on claims data as the main data source to develop effective treatments and medication. However, the static nature of claims data only gives a snapshot of a patient, failing to provide the continuing information that helps research and care teams keep up with the latest virus information.
  6. 6. © 2020 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. Speeding COVID-19 Vaccine Development The virus has also caused major setbacks for clinical trials, now making patients wait even longer to receive experimental treatment for other diseases. Hospitals have braced for an onslaught of critically ill patients, and researchers have had to shelve clinical trials for other illnesses, all in response to COVID-19.
  7. 7. © 2020 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. Speeding COVID-19 Vaccine Development Agencies and clinical-trial funders have shown remarkable flexibility throughout the pandemic. However, research teams need access to near real-time data and insights from the frontlines to assess the long-term effects of COVID-19 on clinical trials and get back on track as soon as possible.
  8. 8. © 2020 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. Speeding COVID-19 Vaccine Development To overcome the lack of data and information about COVID-19, health systems are constantly tracking and recording new data about the virus. Now the primary source of information— de-identified COVID-19 patient data from health systems across the country—is an imperative to creating a vaccine and getting life back to normal.
  9. 9. © 2020 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. A Comprehensive National Data Set and Registry Even though there is no historical COVID-19 patient data, pharmaceutical companies can still leverage comprehensive data for vaccine development and clinical trial processes.
  10. 10. © 2020 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. A Comprehensive National Data Set and Registry The Touchstone® for COVID-19 National Data Sets and Registry allows pharmaceutical companies to access de-identified patient data from more than 80 million patients across the United States (Figure 1), as well as three national data sources (Johns Hopkins University, The New York Times, and The COVID Tracking Project). Now, pharmaceutical companies can tap into a breadth of data to conduct population-based research.
  11. 11. © 2020 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. A Comprehensive National Data Set and Registry COVID-19 National Registry as of August 2, 2020 Figure 1. States with COVID-19 patient data in Touchstone representing 21 health systems.
  12. 12. © 2020 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. A Comprehensive National Data Set and Registry Partnering with Health Catalyst bridges gaps in health data with an ecosystem that spans hospitals, academic medical centers (AMCs), and research institutions across the United States. With unparalleled access to large sums of clinical data, coupled with support and expertise from Health Catalyst leaders to develop real-world insights and evidence, pharmaceutical companies can rely on added bench strength and up-to-date information from a comprehensive COVID-19 registry.
  13. 13. © 2020 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. A Comprehensive National Data Set and Registry The Touchstone COVID-19 National Data Set and Registry goes beyond data, enabling research in unique ways: Providing access to a network of healthcare organizations (hospitals, AMCs, and research institutions) resources, including patients (for clinical trial recruitment and testing), providers, and researchers. Fostering collaboration with health experts about standard-of-care practices to understand how to change and improve clinical care. Discovering deeper insights and connections that go beyond the data (e.g., understanding firsthand how data translates to frontline clinical practice). Testing and implementing new tools (e.g., a prediction tool) at the point of care to identify opportunities to improve clinical care. > > > >
  14. 14. © 2020 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. Insights and Research: The Bedrock for Pharmaceutical Progress and Developments Because knowledge about COVID-19 is continually evolving, the need for population- based research at a national scale is critical. The most effective population-based research includes the latest, point-of-care data that development teams can leverage to steer research and development. Reliable, actionable insights—rather than static, outdated data—allows pharmaceutical organizations to maximize resources in clinical trials, shift direction as the virus changes, and avoid wasting precious resources.
  15. 15. © 2020 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. Insights and Research: The Bedrock for Pharmaceutical Progress and Developments The COVID-19 patient data and population- based research also benefits pharmaceutical companies primarily focused on clinical trials. For example, patients who contract the virus while participating in unrelated clinical trials could steer the outcomes of that trial to misleading endpoints.
  16. 16. © 2020 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. Insights and Research: The Bedrock for Pharmaceutical Progress and Developments Reliable, accurate insights can help clinical trials stay on track in geographic areas that are recovering from COVID- 19 and progress to the planning phase of the COVID-19 framework (Prepare, Prevent, Recover, Plan).
  17. 17. © 2020 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. Getting Research and Development Back on Track with COVID-19 Patient Data COVID-19 also impacts the recruitment process for clinical trials. For example, a lack of understanding about the virus makes it difficult to recruit patients to test new medications that might react negatively with the virus.
  18. 18. © 2020 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. Getting Research and Development Back on Track with COVID-19 Patient Data With access to a wealth of continuing point- of-care data sets across multiple populations, pharmaceutical companies will more quickly understand the virus as it evolves and take this information into account for existing and future clinical trials.
  19. 19. © 2020 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. Getting Research and Development Back on Track with COVID-19 Patient Data Additionally, COVID-19 research will reveal insights that open the door to future collaboration between health systems and pharmaceutical companies. As COVID-19 research and insights reveal clinical practice trends, research teams can use this information to connect with health systems after the pandemic to review trends and opportunities to improve care or develop new treatments.
  20. 20. © 2020 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. Three Critical Components for Pharmaceutical Companies During COVID-19: Insights, Expertise, and Research COVID-19 presents seemingly endless unknowns to pharmaceutical companies, health systems, providers, and patients. These uncertainties can complicate an already complex environment and stall research efforts.
  21. 21. © 2020 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. Three Critical Components for Pharmaceutical Companies During COVID-19: Insights, Expertise, and Research The Touchstone for COVID-19: National Data Sets and Registry offers near real- time patient data with outcomes analysis and clinical trials analysis, so research teams can stay up to date with, and adapt to, the virus.
  22. 22. © 2020 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. Three Critical Components for Pharmaceutical Companies During COVID-19: Insights, Expertise, and Research This comprehensive, population-based research data benefits pharmaceutical companies—both research-focused and clinical trial-focused—by providing de- identified patient data from more than 80 million patients throughout the United States, integrated with three national data sources.
  23. 23. © 2020 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. Three Critical Components for Pharmaceutical Companies During COVID-19: Insights, Expertise, and Research The registry allows research pharmaceutical teams to focus on research and development of the COVID-19 vaccine and conducting clinical trials. With around-the-clock access to the most recent and complete data sets, pharmaceutical companies are prepared to battle the coronavirus with data-informed research and prepare for future healthcare unknowns.
  24. 24. © 2020 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. Published Research: COVID-19 Reinfection Analysis Federated Observational Study of Clinical Therapeutics – Inpatient Famotidine Stratification of Patients by Tumor Type Using Molecular Profiling in Real-World Data > > >
  25. 25. © 2020 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. For more information: “This book is a fantastic piece of work” – Robert Lindeman MD, FAAP, Chief Physician Quality Officer
  26. 26. © 2020 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. More about this topic Link to original article for a more in-depth discussion. Health Catalyst Launches COVID-19 Patient Data Repository to Speed Vaccine Development Using COVID-19 Value Sets for Patient Identification Sadiqa Mahmood, DDS, MPH, General Manager & Senior VP, Life Sciences Business Extended Real-World Data: The Life Science Industry’s Number One Asset (Executive Report) Elia Stupka, PhD, Strategic Advisor Bridging the Data and Trust Gaps: Why Health Catalyst Entered the Life Sciences Market Dale Sanders, Chief Technology Officer Data-Driven Precision Medicine: A Must-Have for the Next-Generation of Personalized Care Alyssa Antonopoulos, Precision Medicine, Associate Director; Elia Stupka, PhD, Strategic Advisor Adem Albayrak, VP of Technology, Life Sciences Business Sadiqa Mahmood, DDS, MPH, General Manager & Senior VP, Life Sciences Business Hospital Capacity Management: How to Prepare for COVID-19 Patient Surges Jason Jones, PhD, Chief Data Scientist; John Hansmann, MSIE, LFHIMSS, DSHS, Professional Services, VP Monica Horvath, Strategic Consultant, Health Intelligence & Product Adoption
  27. 27. © 2020 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. Sadiqa Mahmood, DDS, MPH is the Senior Vice President and General Manager of the Life Sciences business at Health Catalyst and contributes to the overall vision and growth for the company. Sadiqa’s work focuses on identifying and addressing areas of high unmet need for therapeutic development through application of real-world data. She is an advisor to several healthcare organizations and global policy makers. Sadiqa is a dental surgeon and holds a master’s degree in public health from the Harvard School of Public Health. Passionate about improving access to care and patient outcomes by leveraging data and healthcare ecosystem, Sadiqa has spent her career at the intersection of medicine, policy, technology, and analytics. Previously she led clinical analytics, quality and safety, value-based contracting, and population health across healthcare organizations, including the Dana-Farber Cancer Institute, Partners HealthCare System, and Boston Medical Center. Sadiqa has been an advocate of collaborative learning system in healthcare and has steered cross-industry multi-stakeholder national and global collaborations to drive healthcare innovation. She joined Health Catalyst in 2019 as SVP of Medical Affairs. Sadiqa has lived and worked in Asia and UK in addition to the US. She is based in Boston, Massachusetts. Outside of work, she is a Formula 1 fan and race as a member of a local team. Other Clinical Quality Improvement Resources Click to read additional information at www.healthcatalyst.com Sadiqa Mahmood, DDS, MPH
  28. 28. © 2020 Health Catalyst Proprietary. Feel free to share but we would appreciate a Health Catalyst citation. Other Clinical Quality Improvement Resources Click to read additional information at www.healthcatalyst.com Health Catalyst is a mission-driven data warehousing, analytics and outcomes-improvement company that helps healthcare organizations of all sizes improve clinical, financial, and operational outcomes needed to improve population health and accountable care. Our proven enterprise data warehouse (EDW) and analytics platform helps improve quality, add efficiency and lower costs in support of more than 65 million patients for organizations ranging from the largest US health system to forward-thinking physician practices. Health Catalyst was recently named as the leader in the enterprise healthcare BI market in improvement by KLAS, and has received numerous best-place-to work awards including Modern Healthcare in 2013, 2014, and 2015, as well as other recognitions such as “Best Place to work for Millenials, and a “Best Perks for Women.”

×